Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Launched by JEMINCARE · Jan 28, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called JMKX003142 for people with a serious kidney condition known as Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD). The goal is to see if this treatment is safe, effective, and well-tolerated compared to a placebo (a pill that doesn’t contain the active medication). The trial is currently not recruiting participants, but it will focus on adults aged 18 to 55 who have been diagnosed with ADPKD and meet specific criteria for rapid progression of the disease.

To be eligible for the trial, participants need to understand the trial procedures and give their consent. They should not have taken certain medications for ADPKD in the 12 weeks before the trial starts, nor should they have had major surgeries recently. During the trial, participants will receive either the study medication or the placebo and will be monitored closely for their health and response to the treatment. This trial is important because it may help find new ways to treat a challenging condition that affects kidney function.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Able to understand the procedures of this trial and provide written informed consent voluntarily;
• • Age between 18 to 55 years, male or female;
• • ADPKD diagnostic criteria were met before randomization;
• • Rapidly progressive ADPKD criteria were met.
• Exclusion Criteria:
• • 12 weeks prior to screening, patients had taken tolvaptan or another ADPKD improvers, or patients who were assessed by the investigator to be likely to use diuretic during the trial period;
• • Praticipants who are unable to feel thirst, or have difficulty with fluid/food intake;
• • Patients who have previously received decompression surgery for renal cysts; or who received major surgery within 12 weeks before signing the ICF;
• • The investigator think that the praticipant is unable to comply with the requirements of the trial or cannot be evaluated by the trial.